Search

Your search keyword '"Brunetto M."' showing total 93 results

Search Constraints

Start Over You searched for: Author "Brunetto M." Remove constraint Author: "Brunetto M." Publisher elsevier bv Remove constraint Publisher: elsevier bv
93 results on '"Brunetto M."'

Search Results

1. The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories

2. HBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT CLINICAL RELAPSE AND HBSAG LOSS IN HBEAG NEGATIVE PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY

3. Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data

4. Long-term results from the Italian real-world experience on obeticholic acid treatment in primary biliary cholangitis: The RECAPITULATE study

5. Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis

6. Prediction of response to obeticholic acid in primary biliary cholangitis: Development and validation of the OCA response score (ORS)

7. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

8. EE275 Personalised Versus Standard Dosimetry for Selective Internal Radiation Therapy in Patients With Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

9. Predictors of Serious Adverse Event and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis under Obeticholic Acid

10. Clinical features of patients with new onset of autoimmune hepatitis following SARS-CoV-2 vaccination

11. Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study

13. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

14. From current status to optimization of HCV treatment: Recommendations from an expert panel

15. OC.01.6 THE CT1 MULTI-PARAMETRIC MRI VALUE IS MORE SENSITIVE AND RELIABLE THAN TRANSIENT ELASTOGRAPHY FOR THE NON-INVASIVE MONITORING OF INTRA-HEPATIC INFLAMMATION/FIBROSIS RESPONSE TO DAA THERAPY IN CHC PATIENTS

16. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

17. Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy

18. Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use

19. National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing

21. SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study

22. Whole genome viral sequencing reveals subgenotype specific dynamics of antiviral treatment response in HBeAg positive and treatment naive chronic hepatitis B patients

23. IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: a multicenter prospective trial in Italy

24. Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries?

25. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

26. Viral kinetics in women of child bearing potential with chronic hepatitis B virus following treatment with tenofovir alafenamide or tenofovir disoproxil fumarate

27. A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96

28. A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure

29. HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study

31. A Genotype-Specific Baseline Score to Predict Response at 48 Weeks Post-Treatment to Peginterferon Alfa-2a in Patients with HBeAg-Negative Chronic Hepatitis B

32. A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with Hbeag-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results

33. Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana per Lo Studio Della Terapia Delle Epatiti Virali) Cohort Study

34. HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study

36. 251 THERAPY WITH T CELL RECEPTOR GENE MODIFIED T CELLS TARGETING HBsAg-PRODUCING HCC METASTASES

37. 1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY

38. A new experimental snow avalanche test site at Seehore peak in Aosta Valley (NW Italian Alps) ? Part II: Engineering aspects

39. A new experimental snow avalanche test site at Seehore peak in Aosta Valley (NW Italian Alps)—part I: Conception and logistics

41. 522 MAINTAINED VIRAL SUPPRESSION AND EXCELLENT SAFETY PROFILE OF ENTECAVIR MONOTHERAPY IN 418 NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A 4-YEAR FIELD PRACTICE, MULTICENTER STUDY

43. ACKNOWLEDGEMENT OF REVIEWERS

44. 1009 EFFECTIVENESS OF ENTECAVIR FOR NUC-NAIVE, HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY IN 311 PATIENTS

45. OC.03.2 ENTECAVIR FOR NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376 PATIENTS

47. 397 INDIVIDUAL PATIENT DATA META-ANALYSIS OF TRANSIENT ELASTOGRAPHY DIAGNOSTIC ACCURACY IN LIVER FIBROSIS ASSESSMENT OF CHRONIC HEPATITIS C PATIENTS (TE IPD STUDY)

48. 916 ENTECAVIR IS AN EFFECTIVE TREATMENT FOR NUC-NAIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: 48-WEEK DATA FROM A LARGE MULTICENTER COHORT STUDY

50. Effectiveness of entecavir for the treatment of NUC-naïve chronic hepatitis B patients: A large multicenter cohort study in clinical practice

Catalog

Books, media, physical & digital resources